Phase I study of the novel Cdc2/CDK1 and AKT inhibitor terameprocol in patients with advanced leukemias.
Tibes R, McDonagh KT, Lekakis L, Bogenberger JM, Kim S, Frazer N, Mohrland S, Bassett D, Garcia R, Schroeder K, Shanmugam V, Carpten J, Hagelstrom RT, Beaudry C, Von Hoff D, Shea TC.
Tibes R, et al.
Invest New Drugs. 2015 Apr;33(2):389-96. doi: 10.1007/s10637-014-0198-y. Epub 2014 Dec 19.
Invest New Drugs. 2015.
PMID: 25523151
Clinical Trial.